ThermoGenesis
Corp. (Nasdaq: KOOL), a company that develops and markets enabling
technologies for cord blood stem cell therapy and surgical wound care,
announced today that Mr. Philip H. Coelho, the Company's Chairman and Chief
Executive Officer, will be a featured speaker at the International Stem
Cells and Regenerative Medicine 2007 meeting to be held January 22-24, 2007
in San Francisco, California.
Mr. Coelho's presentation, "Maximizing the Therapeutic Potential of
Cord Blood Transplantation Using Automated Devices with Dedicated Closed
System Disposables," will provide an overview of how the company's cell
therapy devices -- AutoXpress(TM) (AXP(TM)) System and BioArchive(R) System
-- automate the cord blood banking process to maximize cell recovery and
viability throughout the cord blood processing, freezing and storage
procedures to enhance clinical efficacy of cord blood transplantation. The
presentation will also suggest additional cell therapies where these
automated systems may have value.
About ThermoGenesis Corp.
ThermoGenesis Corp. (thermogenesis) is a leader in developing
and manufacturing automated blood processing systems and disposable
products that enable the manufacture, preservation and delivery of cell and
tissue therapy products. These products include:
The BioArchive(R) System, an automated cryogenic device, is used by
cord blood stem cell banks in more than 25 countries for
cryopreserving and archiving cord blood stem cell units for
transplant. GE Healthcare is the non-exclusive global distribution
partner for the BioArchive System.
The AutoXpress System (AXP(TM)), is a newly developed semi-automated
device and companion sterile closed blood processing disposable, to
harvest stem cells from cord blood. GE Healthcare is the exclusive
global distribution partner for the AXP AutoXpress System.
The CryoSeal(R) FS System, an automated device and companion sterile
blood processing disposable, is used to prepare fibrin sealants from
plasma in about an hour. A 150-patient U.S. pivotal clinical trial
has been completed and a pre-market approval application (PMA) is
being reviewed by the FDA. The CryoSeal FS System has received the
CE-Mark. From a marketing perspective, the CE Mark is the European
equivalent to an FDA approval, in that it allows sales of the
product throughout the European community.
The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood
processing disposable that prepares activated thrombin from a small
aliquot of plasma in less than 30 minutes. The CE-Marked TPD is
currently being marketed in Europe by Biomet, Inc., subsidiary
Biomet Biologics, Medtronic, Inc. and independent distributors.
This press release, including statements regarding financial
information for future periods, contain forward-looking statements, and such statements
are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors,
including timing of FDA approvals, changes in customer forecasts, our failure to
meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2007, and introduction of competitive products and other factors
beyond our control, could result in a materially different revenue outcome
and/or in our failure to achieve the revenue levels we expect for fiscal 2007. A
more complete description of these and other risks that could cause actual
events to differ from the outcomes predicted by our forward looking
statements is set forth under the caption "Risk Factors" in our annual report on Form
10-K and other reports we file with the Securities and Exchange Commission
from time to time, and you should consider each of those factors when evaluating the forward looking statements.
ThermoGenesis Corp.
thermogenesis